About the GAD-7
The GAD-7 was developed by Spitzer et al. (2006) and validated against structured clinical interviews. It has a sensitivity of 89% and specificity of 82% for GAD at a cutoff of 10 or above. It also screens reasonably well for panic disorder, social anxiety, and PTSD, making it useful as a general anxiety screening instrument even when GAD is not the primary suspected diagnosis. Anxiety disorders as a group are the most common mental health conditions in the US, according to the National Institute of Mental Health.
Severity classification and treatment
The suggested actions below follow the stepped-care approach set out in NICE Guideline CG113, matching treatment intensity to symptom severity rather than defaulting straight to medication.
| Score | Severity | Suggested action |
|---|---|---|
| 0-4 | Minimal anxiety | Monitor. Provide psychoeducation if symptoms are distressing. |
| 5-9 | Mild anxiety | Watchful waiting. Guided self-help, relaxation techniques, lifestyle advice. |
| 10-14 | Moderate anxiety | Consider active treatment: CBT, stepped care, or pharmacotherapy (SSRIs/SNRIs). |
| 15-21 | Severe anxiety | Refer to mental health services. Active pharmacotherapy. Safety assessment if indicated. |
Ruling Out Physical Causes
Several physical conditions can produce anxiety-like symptoms and should be considered, especially with new-onset symptoms in someone with no prior anxiety history. Hyperthyroidism is the classic example, causing nervousness, tremor, palpitations, and sleep disturbance that can closely mimic GAD. Thyroid function tests (TSH, free T4) are a standard part of the initial workup; if results come back in different units than expected, our Lab Values Converter handles the mmol/L and pmol/L conversions.
Anxiety and Cardiovascular Risk
Anxiety disorders are associated with a modestly elevated long-term cardiovascular risk, and the physical symptoms of anxiety, palpitations and chest tightness in particular, can be difficult to distinguish from cardiac symptoms without further assessment. For patients with cardiovascular risk factors alongside anxiety, the Framingham Risk Score can help frame the conversation about overall risk.
GAD-2 as an initial screen
Items 1 and 2 of the GAD-7 (feeling nervous/anxious and not being able to control worry) form the GAD-2. A score of 3 or above on the GAD-2 warrants full GAD-7 completion. Sensitivity 86%, specificity 83% for GAD at this cutoff.
Comorbidity with depression
Anxiety and depression frequently co-occur. If a patient screens positive on the GAD-7, always consider completing the PHQ-9 as well. PHQ-9 and GAD-7 together in 10 minutes give a comprehensive picture of the most common mental health presentations in primary care.
Related tools
For depression screening, see PHQ-9. For stress assessment, see Perceived Stress Scale. For burnout, see Burnout Index. For sleep quality, see Sleep Quality Score.
References
- Spitzer RL, et al. "A brief measure for assessing generalized anxiety disorder." Arch Intern Med. 2006;166(10):1092-1097.
- NICE Guideline CG113. Generalised anxiety disorder and panic disorder in adults. NICE, 2011 (updated 2019).